SCHEMBL21138114

SCHEMBL21138114

CCCC(=O)N[C@H]1C(O)O[C@H](COC(=O)CCC(O)O)[C@@H](O)[C@@H]1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PYGB P11216 1/20 0.40
▸ TLR4 O00206 3/20 0.38
▸ AMDHD2 Q9Y303 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PRKD3 O94806 1/20 0.33
▸ PRKCG P05129 1/20 0.33
▸ PRKCB P05771 1/20 0.33
▸ PRKCA P17252 1/20 0.33
▸ PRKCH P24723 1/20 0.33
▸ PRKCI P41743 1/20 0.33
▸ PRKCE Q02156 1/20 0.33
▸ PRKCQ Q04759 1/20 0.33
▸ PRKCZ Q05513 1/20 0.33
▸ PRKCD Q05655 1/20 0.33
▸ PRKD1 Q15139 1/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ HK1 P19367 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137953 0.90 PYGB (0.45) PYGBTLR4AMDHD2KDM4ELMNA
SCHEMBL21138039 0.90 PYGB (0.45) PYGBTLR4AMDHD2KDM4ELMNA
SCHEMBL23104873 0.87 PYGB (0.48) PYGBTLR4AMDHD2KDM4ELMNA
SCHEMBL21138044 0.87 PYGB (0.48) PYGBTLR4AMDHD2KDM4ELMNA
SCHEMBL21137986 0.86 PYGB (0.41) PYGBTLR4AMDHD2KDM4ELMNA
SCHEMBL21137910 0.85 TLR4 (0.44) PYGBTLR4MAPK1
SCHEMBL31353005 0.85 TLR4 (0.44) PYGBTLR4MAPK1
SCHEMBL21137960 0.84 PYGB (0.40) PYGBTLR4AMDHD2KDM4ELMNA
SCHEMBL21137917 0.84 PYGB (0.40) PYGBTLR4AMDHD2KDM4ELMNA
Hydrochloric Acid SCHEMBL31353008 0.83 PYGB (0.41) PYGBTLR4AMDHD2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885TLR4 896/4885AMDHD2 51/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA PYGB 601/4885TLR4 896/4885AMDHD2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback